BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hermans LE, Svicher V, Pas SD, Salpini R, Alvarez M, Ben Ari Z, Boland G, Bruzzone B, Coppola N, Seguin-Devaux C, Dyda T, Garcia F, Kaiser R, Köse S, Krarup H, Lazarevic I, Lunar MM, Maylin S, Micheli V, Mor O, Paraschiv S, Paraskevis D, Poljak M, Puchhammer-Stöckl E, Simon F, Stanojevic M, Stene-Johansen K, Tihic N, Trimoulet P, Verheyen J, Vince A, Weis N, Yalcinkaya T, Lepej SZ, Perno C, Boucher CA, Wensing AM; HEPVIR Working Group of the European Society for Translational Antiviral Research. Combined Analysis of the Prevalence of Drug-Resistant Hepatitis B Virus in Antiviral Therapy-Experienced Patients in Europe (CAPRE). J Infect Dis 2016;213:39-48. [PMID: 26136470 DOI: 10.1093/infdis/jiv363] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 3.1] [Reference Citation Analysis]
Number Citing Articles
1 Ostankova YV, Serikova EN, Semenov AV, Zueva EB, Valutite DE, Schemelev AN, Zurochka VA, Totolian AA. Molecular and genetic characterization of the hepatitis B virus full-length genome sequences identified in HBsAg-negative blood donors in Ural Federal District. Journal of microbiology, epidemiology and immunobiology 2023;99:637-650. [DOI: 10.36233/0372-9311-325] [Reference Citation Analysis]
2 King RE, Kimotho J, Macharia R, Ndung’u FN, Nzou SM, Irekwa RM. Identification and Characterization of Hepatitis B Virus Immune Escape Mutants in Kenya. AJMB 2023;13:1-17. [DOI: 10.4236/ajmb.2023.131001] [Reference Citation Analysis]
3 Mokaya J, Vasylyeva TI, Barnes E, Ansari MA, Pybus OG, Matthews PC. Global prevalence and phylogeny of hepatitis B virus (HBV) drug and vaccine resistance mutations. J Viral Hepat 2021;28:1110-20. [PMID: 33893696 DOI: 10.1111/jvh.13525] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Liang J, Liang X, Ma H, Nie L, Tian Y, Chen G, Wang Y. Detection of Hepatitis B Virus M204V Mutation Quantitatively via Real-time PCR. J Clin Transl Hepatol 2021;9:143-8. [PMID: 34007795 DOI: 10.14218/JCTH.2020.00118] [Reference Citation Analysis]
5 Mokaya J, Vasylyeva TI, Barnes E, Ansari MA, Pybus OG, Matthews PC. Global prevalence and phylogeny of hepatitis B virus (HBV) drug and vaccine resistance mutations.. [DOI: 10.1101/2020.10.07.329391] [Reference Citation Analysis]
6 Mokaya J, McNaughton AL, Bester PA, Goedhals D, Barnes E, Marsden BD, Matthews PC. Hepatitis B virus resistance to tenofovir: fact or fiction? Wellcome Open Res. 2020;5:151. [PMID: 33869791 DOI: 10.12688/wellcomeopenres.15992.1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
7 Wang S, Li H, Kou Z, Ren F, Jin Y, Yang L, Dong X, Yang M, Zhao J, Liu H, Dong N, Jia L, Chen X, Zhou Y, Qiu S, Hao R, Song H. Highly sensitive and specific detection of hepatitis B virus DNA and drug resistance mutations utilizing the PCR-based CRISPR-Cas13a system. Clin Microbiol Infect 2021;27:443-50. [PMID: 32360447 DOI: 10.1016/j.cmi.2020.04.018] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
8 Lu S, Yang X, Jiang T, Zhou H, Wang W, Lin N, Zeng S, Ma Z, Jiang H. Pregnancy Impacts Entecavir Pharmacokinetics but Does Not Alter Its Renal Excretion. J Pharm Sci 2020;109:1811-8. [PMID: 32027922 DOI: 10.1016/j.xphs.2020.01.027] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
9 Ma Z, Lu S, Sun D, Bai M, Jiang T, Lin N, Zhou H, Zeng S, Jiang H. Roles of organic anion transporter 2 and equilibrative nucleoside transporter 1 in hepatic disposition and antiviral activity of entecavir during non-pregnancy and pregnancy. Br J Pharmacol 2019;176:3236-49. [PMID: 31166004 DOI: 10.1111/bph.14756] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
10 Tillmann HL, Samuel G. Current state-of-the-art pharmacotherapy for the management of hepatitis B infection. Expert Opin Pharmacother 2019;20:873-85. [PMID: 30857443 DOI: 10.1080/14656566.2019.1583744] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
11 Lam AM, Espiritu C, Vogel R, Ren S, Lau V, Kelly M, Kuduk SD, Hartman GD, Flores OA, Klumpp K. Preclinical Characterization of NVR 3-778, a First-in-Class Capsid Assembly Modulator against Hepatitis B Virus. Antimicrob Agents Chemother 2019;63:e01734-18. [PMID: 30373799 DOI: 10.1128/AAC.01734-18] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 5.2] [Reference Citation Analysis]
12 Alacam S, Karabulut N, Yolcu A, Onel M, Atasoy A, Kaymakoglu S, Agacfidan A. Evaluation of drug resistance mutations in patients with chronic hepatitis B. Folia Microbiol (Praha) 2019;64:237-43. [PMID: 30259350 DOI: 10.1007/s12223-018-0650-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
13 Mokaya J, McNaughton AL, Hadley MJ, Beloukas A, Geretti AM, Goedhals D, Matthews PC. A systematic review of hepatitis B virus (HBV) drug and vaccine escape mutations in Africa: A call for urgent action. PLoS Negl Trop Dis 2018;12:e0006629. [PMID: 30080852 DOI: 10.1371/journal.pntd.0006629] [Cited by in Crossref: 41] [Cited by in F6Publishing: 44] [Article Influence: 8.2] [Reference Citation Analysis]
14 Colagrossi L, Hermans LE, Salpini R, Di Carlo D, Pas SD, Alvarez M, Ben-Ari Z, Boland G, Bruzzone B, Coppola N, Seguin-Devaux C, Dyda T, Garcia F, Kaiser R, Köse S, Krarup H, Lazarevic I, Lunar MM, Maylin S, Micheli V, Mor O, Paraschiv S, Paraskevis D, Poljak M, Puchhammer-Stöckl E, Simon F, Stanojevic M, Stene-Johansen K, Tihic N, Trimoulet P, Verheyen J, Vince A, Lepej SZ, Weis N, Yalcinkaya T, Boucher CAB, Wensing AMJ, Perno CF, Svicher V; HEPVIR working group of the European Society for translational antiviral research (ESAR). Immune-escape mutations and stop-codons in HBsAg develop in a large proportion of patients with chronic HBV infection exposed to anti-HBV drugs in Europe. BMC Infect Dis 2018;18:251. [PMID: 29859062 DOI: 10.1186/s12879-018-3161-2] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 5.0] [Reference Citation Analysis]
15 Guo X, Wu J, Wei F, Ouyang Y, Li Q, Liu K, Wang Y, Zhang Y, Chen D. Trends in hepatitis B virus resistance to nucleoside/nucleotide analogues in North China from 2009-2016: A retrospective study. Int J Antimicrob Agents 2018;52:201-9. [PMID: 29654894 DOI: 10.1016/j.ijantimicag.2018.04.002] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 4.6] [Reference Citation Analysis]
16 Mokaya J, Mcnaughton AL, Hadley MJ, Beloukas A, Geretti A, Goedhals D, Matthews PC. A systematic review of Hepatitis B virus (HBV) drug and vaccine escape mutations in Africa: a call for urgent action.. [DOI: 10.1101/258350] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
17 Liu B, Yang JX, Yan L, Zhuang H, Li T. Novel HBV recombinants between genotypes B and C in 3'-terminal reverse transcriptase (RT) sequences are associated with enhanced viral DNA load, higher RT point mutation rates and place of birth among Chinese patients. Infect Genet Evol 2018;57:26-35. [PMID: 29111272 DOI: 10.1016/j.meegid.2017.10.023] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
18 Ma Z, Yang X, Jiang T, Bai M, Zheng C, Zeng S, Sun D, Jiang H. Multiple SLC and ABC Transporters Contribute to the Placental Transfer of Entecavir. Drug Metab Dispos 2017;45:269-78. [DOI: 10.1124/dmd.116.073304] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 4.0] [Reference Citation Analysis]
19 Beloukas A, Geretti AM. Hepatitis B Virus Drug Resistance. Antimicrobial Drug Resistance 2017. [DOI: 10.1007/978-3-319-47266-9_26] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
20 Wyles D, Lin J. Clinical Manifestations of Acute and Chronic Hepatitis. Infectious Diseases 2017. [DOI: 10.1016/b978-0-7020-6285-8.00042-3] [Reference Citation Analysis]
21 Meng T, Shi X, Gong X, Deng H, Huang Y, Shan X, Shan Y, Huang A, Long Q. Analysis of the prevalence of drug-resistant hepatitis B virus in patients with antiviral therapy failure in a Chinese tertiary referral liver centre (2010-2014). J Glob Antimicrob Resist 2017;8:74-81. [PMID: 28017671 DOI: 10.1016/j.jgar.2016.10.012] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.9] [Reference Citation Analysis]
22 Li X, Liu Y, Xin S, Ji D, You S, Hu J, Zhao J, Wu J, Liao H, Zhang XX. Comparison of Detection Rate and Mutational Pattern of Drug-Resistant Mutations Between a Large Cohort of Genotype B and Genotype C Hepatitis B Virus-Infected Patients in North China. Microb Drug Resist. 2016; Oct 28. [Epub ahead of print]. [PMID: 27792585 DOI: 10.1089/mdr.2016.0093] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
23 Chantratita W, Song KS, Pongthanapisith V, Thongbaiphet N, Angkanavin K, Nimse SB, Sonawane MD, Kim T. HBV/4DR 9G test and its comparison with INNO-LiPA HBV multi-DR test for the detection of drug-resistant Hepatitis B virus. J Virol Methods 2016;237:58-63. [PMID: 27581951 DOI: 10.1016/j.jviromet.2016.08.016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
24 Archampong TN, Boyce CL, Lartey M, Sagoe KW, Obo-Akwa A, Kenu E, Blackard JT, Kwara A. HBV genotypes and drug resistance mutations in antiretroviral treatment-naive and treatment-experienced HBV-HIV-coinfected patients. Antivir Ther. 2017;22:13-20. [PMID: 27167598 DOI: 10.3851/imp3055] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
25 [DOI: 10.1101/19009563] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Reference Citation Analysis]